

# Ilze Bot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2989867/publications.pdf>

Version: 2024-02-01

104  
papers

4,972  
citations

81743

39  
h-index

102304

66  
g-index

104  
all docs

104  
docs citations

104  
times ranked

7257  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis. <i>Circulation Research</i> , 2008, 102, 209-217.	2.0	363
2	SDF-1 $\alpha$ /CXCR4 Axis Is Instrumental in Neointimal Hyperplasia and Recruitment of Smooth Muscle Progenitor Cells. <i>Circulation Research</i> , 2005, 96, 784-791.	2.0	345
3	Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. <i>Circulation Research</i> , 2020, 127, 1437-1455.	2.0	283
4	Perivascular Mast Cells Promote Atherogenesis and Induce Plaque Destabilization in Apolipoprotein E-Deficient Mice. <i>Circulation</i> , 2007, 115, 2516-2525.	1.6	248
5	Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studies. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 18-30.	2.0	176
6	Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. <i>Journal of Experimental Medicine</i> , 2011, 208, 217-225.	4.2	168
7	Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1653-1659.	1.1	136
8	Mast Cells as Effectors in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 265-271.	1.1	115
9	Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. <i>British Journal of Pharmacology</i> , 2014, 171, 723-734.	2.7	95
10	Mast cells in human and experimental cardiometabolic diseases. <i>Nature Reviews Cardiology</i> , 2015, 12, 643-658.	6.1	95
11	Myocardin Regulates Vascular Smooth Muscle Cell Inflammatory Activation and Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 817-828.	1.1	92
12	Y-Box Binding Protein-1 Controls CC Chemokine Ligand-5 (CCL5) Expression in Smooth Muscle Cells and Contributes to Neointima Formation in Atherosclerosis-Prone Mice. <i>Circulation</i> , 2007, 116, 1812-1820.	1.6	91
13	Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression. <i>Nature Communications</i> , 2016, 7, 10846.	5.8	87
14	Quaking, an RNA-Binding Protein, Is a Critical Regulator of Vascular Smooth Muscle Cell Phenotype. <i>Circulation Research</i> , 2013, 113, 1065-1075.	2.0	86
15	Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. <i>European Heart Journal</i> , 2013, 34, 3699-3706.	1.0	85
16	Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. <i>Atherosclerosis</i> , 2011, 218, 53-60.	0.4	83
17	Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. <i>Blood</i> , 2007, 109, 122-129.	0.6	73
18	Vaccination against Foxp3+ regulatory T cells aggravates atherosclerosis. <i>Atherosclerosis</i> , 2010, 209, 74-80.	0.4	72

#	ARTICLE	IF	CITATIONS
19	Short Communication: The Neuropeptide Substance P Mediates Adventitial Mast Cell Activation and Induces Intraplaque Hemorrhage in Advanced Atherosclerosis. <i>Circulation Research</i> , 2010, 106, 89-92.	2.0	62
20	Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE <sup>-/-</sup> / $\alpha^{\text{v}}$ mice. <i>Cardiovascular Research</i> , 2011, 89, 244-252.	1.8	61
21	Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE <sup>-/-</sup> / $\alpha^{\text{v}}$ Mice. <i>Circulation Research</i> , 2003, 93, 464-471.	2.0	59
22	Mast cells in atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 820-826.	1.8	59
23	Scavenger Receptor-AL $\alpha^{\text{v}}$ -Targeted Iron Oxide Nanoparticles for In Vivo MRI Detection of Atherosclerotic Lesions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1812-1819.	1.1	59
24	Leukocyte-Specific CCL3 Deficiency Inhibits Atherosclerotic Lesion Development by Affecting Neutrophil Accumulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, e75-83.	1.1	59
25	Atherosclerotic Lesion Progression Changes Lysophosphatidic Acid Homeostasis to Favor its Accumulation. <i>American Journal of Pathology</i> , 2010, 176, 3073-3084.	1.9	58
26	Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury. <i>American Journal of Pathology</i> , 2010, 177, 2753-2764.	1.9	55
27	Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. <i>Journal of Lipid Research</i> , 2013, 54, 1265-1274.	2.0	55
28	Increased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency. <i>Circulation Research</i> , 2017, 120, 78-84.	2.0	52
29	Interruption of the OX40 $\alpha^{\text{v}}$ -OX40 Ligand Pathway in LDL Receptor $\alpha^{\text{v}}$ -Deficient Mice Causes Regression of Atherosclerosis. <i>Journal of Immunology</i> , 2013, 191, 4573-4580.	0.4	51
30	A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy. <i>Scientific Reports</i> , 2017, 7, 52.	1.6	50
31	Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 188-194.	1.1	49
32	Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. <i>Cardiovascular Research</i> , 2013, 97, 311-320.	1.8	49
33	Mast Cells Induce Vascular Smooth Muscle Cell Apoptosis via a Toll-Like Receptor 4 Activation Pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1960-1969.	1.1	48
34	Mast cells in atherosclerotic cardiovascular disease $\alpha^{\text{v}}$ Activators and actions. <i>European Journal of Pharmacology</i> , 2017, 816, 37-46.	1.7	47
35	Nuclear Receptor Nurr1 Is Expressed In and Is Associated With Human Restenosis and Inhibits Vascular Lesion Formation In Mice Involving Inhibition of Smooth Muscle Cell Proliferation and Inflammation. <i>Circulation</i> , 2010, 121, 2023-2032.	1.6	46
36	Myocardin Regulates Vascular Response to Injury Through miR-24/-29a and Platelet-Derived Growth Factor Receptor- $\beta^{\text{v}}$ . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2355-2365.	1.1	46

#	ARTICLE	IF	CITATIONS
37	Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. <i>Atherosclerosis</i> , 2010, 211, 84-89.	0.4	45
38	Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. <i>Atherosclerosis</i> , 2011, 214, 295-300.	0.4	44
39	CXCR4 blockade induces atherosclerosis by affecting neutrophil function. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 74, 44-52.	0.9	44
40	Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. <i>Atherosclerosis</i> , 2015, 241, 289-296.	0.4	42
41	CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. <i>Cardiovascular Research</i> , 2019, 115, 729-738.	1.8	41
42	T-Cell Immunoglobulin and Mucin Domain 3 Acts as a Negative Regulator of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2558-2565.	1.1	40
43	Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo. <i>Blood</i> , 2005, 106, 1147-1153.	0.6	39
44	Inhibition of MicroRNA-494 Reduces Carotid Artery Atherosclerotic Lesion Development and Increases Plaque Stability. <i>Annals of Surgery</i> , 2015, 262, 841-848.	2.1	39
45	Complement factor C5a induces atherosclerotic plaque disruptions. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 2020-2030.	1.6	36
46	Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. <i>Journal of Vascular Surgery</i> , 2009, 50, 152-160.	0.6	35
47	Mast Cells in Cardiovascular Disease: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3395.	1.8	34
48	Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. <i>Cardiovascular Research</i> , 2008, 81, 278-285.	1.8	33
49	Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing <sc>SDF</sc> in a rat model. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2311-2320.	1.6	31
50	Viral Cross-Class Serpin Inhibits Vascular Inflammation and T Lymphocyte Fratricide; A Study in Rodent Models In Vivo and Human Cell Lines In Vitro. <i>PLoS ONE</i> , 2012, 7, e44694.	1.1	31
51	Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. <i>Atherosclerosis</i> , 2014, 235, 196-203.	0.4	31
52	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	1.8	30
53	The Serpin Saga; Development of a New Class of Virus Derived Anti-Inflammatory Protein Immunotherapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2009, 666, 132-156.	0.8	29
54	Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. <i>Cardiovascular Research</i> , 2014, 101, 277-287.	1.8	27

#	ARTICLE	IF	CITATIONS
55	The impact of mast cells on cardiovascular diseases. <i>European Journal of Pharmacology</i> , 2016, 778, 103-115.	1.7	26
56	Flow Cytometry-Based Characterization of Mast Cells in Human Atherosclerosis. <i>Cells</i> , 2019, 8, 334.	1.8	26
57	Hematopoietic Sphingosine 1-Phosphate Lyase Deficiency Decreases Atherosclerotic Lesion Development in LDL-Receptor Deficient Mice. <i>PLoS ONE</i> , 2013, 8, e63360.	1.1	26
58	RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner. <i>Atherosclerosis</i> , 2015, 238, 132-139.	0.4	25
59	Low-Dose FK506 Blocks Collar-Induced Atherosclerotic Plaque Development and Stabilizes Plaques in ApoE <sup>-/-</sup> Mice. <i>American Journal of Transplantation</i> , 2005, 5, 1204-1215.	2.6	24
60	Oxidized Low-Density Lipoprotein-Induced Apoptotic Dendritic Cells as a Novel Therapy for Atherosclerosis. <i>Journal of Immunology</i> , 2015, 194, 2208-2218.	0.4	24
61	Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice. <i>Scientific Reports</i> , 2016, 6, 37585.	1.6	23
62	Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner. <i>Atherosclerosis</i> , 2018, 275, 214-224.	0.4	23
63	Interference of the CD30-CD30L Pathway Reduces Atherosclerosis Development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2862-2868.	1.1	22
64	An Unexpected Intriguing Effect of Toll-Like Receptor Regulator RP105 (CD180) on Atherosclerosis Formation With Alterations on B-Cell Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2810-2817.	1.1	22
65	Local Mast Cell Activation Promotes Neovascularization. <i>Cells</i> , 2020, 9, 701.	1.8	22
66	Mast cells in rheumatic disease. <i>European Journal of Pharmacology</i> , 2016, 778, 116-124.	1.7	21
67	Stress-induced mast cell activation contributes to atherosclerotic plaque destabilization. <i>Scientific Reports</i> , 2019, 9, 2134.	1.6	21
68	Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells. <i>Cardiovascular Research</i> , 2021, 117, 1309-1324.	1.8	21
69	Adenosine A <sub>2B</sub> Receptor Agonism Inhibits Neointimal Lesion Development After Arterial Injury in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2197-2205.	1.1	20
70	Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. <i>Atherosclerosis</i> , 2018, 268, 152-156.	0.4	20
71	Mast Cells: Pivotal Players in Cardiovascular Diseases. <i>Current Cardiology Reviews</i> , 2008, 4, 170-178.	0.6	19
72	Deficiency of the TLR4 analogue RP105 aggravates vein graft disease by inducing a pro-inflammatory response. <i>Scientific Reports</i> , 2016, 6, 24248.	1.6	18

#	ARTICLE	IF	CITATIONS
73	Stressed brain, stressed heart?. <i>Lancet, The</i> , 2017, 389, 770-771.	6.3	18
74	Defective Autophagy in T Cells Impairs the Development of Diet-Induced Hepatic Steatosis and Atherosclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2937.	2.2	16
75	Antisense Oligonucleotide Inhibition of MicroRNA-494 Halts Atherosclerotic Plaque Progression and Promotes Plaque Stabilization. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 638-649.	2.3	16
76	Hematopoietic G-protein-coupled receptor kinase 2 deficiency decreases atherosclerotic lesion formation in LDL receptor-knockout mice. <i>FASEB Journal</i> , 2013, 27, 265-276.	0.2	15
77	Hypercholesterolemia Induces a Mast Cell-CD4+ T Cell Interaction in Atherosclerosis. <i>Journal of Immunology</i> , 2019, 202, 1531-1539.	0.4	15
78	CD39 identifies a microenvironment-specific anti-inflammatory CD8+ T-cell population in atherosclerotic lesions. <i>Atherosclerosis</i> , 2019, 285, 71-78.	0.4	15
79	Circulating Immunoglobulins Are Not Associated with Intraplaque Mast Cell Number and Other Vulnerable Plaque Characteristics in Patients with Carotid Artery Stenosis. <i>PLoS ONE</i> , 2014, 9, e88984.	1.1	15
80	B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells. <i>Cardiovascular Research</i> , 2020, 116, 295-305.	1.8	13
81	Inhibition of microRNA-494-3p activates Wnt signaling and reduces proinflammatory macrophage polarization in atherosclerosis. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1228-1239.	2.3	13
82	Disruption of a CD1d-mediated interaction between mast cells and NKT cells aggravates atherosclerosis. <i>Atherosclerosis</i> , 2019, 280, 132-139.	0.4	12
83	Agonistic Anti-TIGIT Treatment Inhibits T Cell Responses in LDLr Deficient Mice without Affecting Atherosclerotic Lesion Development. <i>PLoS ONE</i> , 2013, 8, e83134.	1.1	11
84	Magnetic resonance imaging contrast-enhancement with superparamagnetic iron oxide nanoparticles amplifies macrophage foam cell apoptosis in human and murine atherosclerosis. <i>Cardiovascular Research</i> , 2023, 118, 3346-3359.	1.8	11
85	Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 740531.	1.1	10
86	Identification of an Internalising Peptide in Differentiated Calu-3 Cells by Phage Display Technology; Application to Gene Delivery to the Airways. <i>Journal of Drug Targeting</i> , 2003, 11, 383-390.	2.1	8
87	Mutation in KERA Identified by Linkage Analysis and Targeted Resequencing in a Pedigree with Premature Atherosclerosis. <i>PLoS ONE</i> , 2014, 9, e98289.	1.1	8
88	Selective Modulation of Nuclear Factor of Activated T-Cell Function in Restenosis by a Potent Bipartite Peptide Inhibitor. <i>Circulation Research</i> , 2012, 110, 200-210.	2.0	7
89	Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display. <i>FASEB Journal</i> , 2013, 27, 4136-4146.	0.2	7
90	The role of mast cells in atherosclerosis. <i>Hamostaseologie</i> , 2015, 35, 113-120.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Low human and murine Mcl-1 expression leads to a pro-apoptotic plaque phenotype enriched in giant-cells. <i>Scientific Reports</i> , 2019, 9, 14547.	1.6	5
92	Induction of HLA-A2 restricted CD8 T cell responses against ApoB100 peptides does not affect atherosclerosis in a humanized mouse model. <i>Scientific Reports</i> , 2019, 9, 17391.	1.6	5
93	Tc17 CD8+ T cells accumulate in murine atherosclerotic lesions, but do not contribute to early atherosclerosis development. <i>Cardiovascular Research</i> , 2021, 117, 2755-2766.	1.8	5
94	The complexity of substance P-mediated mast cell activation. <i>Nature Reviews Cardiology</i> , 2017, 14, 124-124.	6.1	4
95	Uremia does not affect neointima formation in mice. <i>Scientific Reports</i> , 2017, 7, 6496.	1.6	4
96	Leukocyte Bim deficiency does not impact atherogenesis in <i>Ldlr</i> <sup>-/-</sup> mice, despite a pronounced induction of autoimmune inflammation. <i>Scientific Reports</i> , 2017, 7, 3086.	1.6	4
97	High LDL levels lessen bone destruction during antigen-induced arthritis by inhibiting osteoclast formation and function. <i>Bone</i> , 2020, 130, 115140.	1.4	4
98	Mast Cell Distribution in Human Carotid Atherosclerotic Plaque Differs Significantly by Histological Segment. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 808-815.	0.8	4
99	The Mast Cell. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1337-1338.	1.1	3
100	The origin of atherosclerotic plaque cells: Plasticity or not?. <i>Atherosclerosis</i> , 2016, 251, 536-537.	0.4	2
101	Viral serine protease inhibitors as anti-atherosclerotic therapy. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 729-35.	2.3	2
102	Reply to: "The "cholesterol paradox" in patients with mastocytosis". <i>Atherosclerosis</i> , 2019, 284, 262-263.	0.4	1
103	Relaxing the artery: A new strategy to limit atherogenesis. <i>Atherosclerosis</i> , 2016, 251, 510-511.	0.4	0
104	Reply to "Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner". <i>Atherosclerosis</i> , 2018, 278, 323-324.	0.4	0